Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.
CITATION STYLE
Chellappan, D. K., Bhandare, R. R., Shaik, A. B., Prasad, K., Suhaimi, N. A. A., Yap, W. S., … Dua, K. (2022, August 1). Vaccine for Diabetes—Where Do We Stand? International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms23169470
Mendeley helps you to discover research relevant for your work.